Enrollment is now complete for Vir Biotechnology’s global ECLIPSE 1 trial, which is testing the combination treatment of tobevibart and…
Articles by Marisa Wexler, MS
Exposure to a human-made chemical called perfluoroheptanoic acid (PFHpA) may increase the risk and severity of fatty liver disease…
The European Medicines Agency (EMA) has granted orphan drug designation to Suzhou Ribo Life Science’s experimental therapy RBD1016 for…
Oct. 29 is Global PSC Awareness Day, and advocates around the world are joining forces to shine a light on…
A long-term ketogenic diet, which favors fats over carbs, may promote weight loss, but it can also cause fatty…
AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing…
Kezar Life Sciences has hit a roadblock in plans to develop zetomipzomib, its experimental treatment for autoimmune…
A new dataset from genomics company Helix aims to accelerate research into metabolic dysfunction-associated steatohepatitis (MASH), a severe form…
A Phase 1 clinical trial testing PBGENE-HBV, a gene-editing therapy for chronic hepatitis B, is now recruiting patients…
Women with primary biliary cholangitis (PBC) may be at increased risk of having disease flares in the months following…